{"id":74989,"date":"2026-08-17T13:37:24","date_gmt":"2026-08-17T05:37:24","guid":{"rendered":"https:\/\/flcube.com\/?p=74989"},"modified":"2026-08-17T13:37:25","modified_gmt":"2026-08-17T05:37:25","slug":"hengrui-pharmaceuticals-wins-nmpa-clearance-for-phase-ii-trial-of-hrs-4729-a-triple-agonist-peptide-drug-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=74989","title":{"rendered":"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that its drug <strong>HRS\u20114729<\/strong> has received <strong>clinical trial approval from the National Medical Products Administration (NMPA)<\/strong> to proceed with <strong>Phase II clinical trials<\/strong> in adult patients with <strong>type 2 diabetes<\/strong>. The clearance advances one of China&#8217;s growing pipeline of next\u2011generation incretin\u2011based metabolic therapies.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval \u2013 Phase II<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HRS\u20114729 (self\u2011developed peptide drug; triple agonist)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Type 2 diabetes in adult patients<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>12 Aug 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Initiation of Phase II studies assessing efficacy and safety in adults with type 2 diabetes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>HRS\u20114729<\/strong>, a <strong>self\u2011developed peptide drug<\/strong> functioning as a <strong>triple agonist<\/strong><\/li>\n\n\n\n<li><strong>Targets:<\/strong> Simultaneously activates three metabolic receptors \u2014 <strong>GLP\u20111R<\/strong> (glucagon\u2011like peptide\u20111 receptor), <strong>GIPR<\/strong> (glucose\u2011dependent insulinotropic polypeptide receptor), and <strong>GCGR<\/strong> (glucagon receptor)<\/li>\n\n\n\n<li><strong>Pharmacological Actions:<\/strong> Suppresses appetite, delays gastric emptying, enhances insulin sensitivity, and increases energy expenditure in vivo<\/li>\n\n\n\n<li><strong>Therapeutic Effects:<\/strong> Combined actions promote <strong>weight loss<\/strong>, <strong>glycemic control<\/strong>, and improved <strong>glucose and lipid metabolism<\/strong>, ultimately achieving therapeutic efficacy in treating type 2 diabetes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Next\u2011Generation Incretin Race:<\/strong> Triple agonism targeting GLP\u20111R\/GIPR\/GCGR represents the frontier beyond currently dominant single and dual agonists, with the glucagon component designed to drive additional energy expenditure and lipid benefits.<\/li>\n\n\n\n<li><strong>Massive Addressable Market:<\/strong> China has the world&#8217;s largest type 2 diabetes population, and demand for therapies combining glycemic control with weight reduction continues to expand rapidly.<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> With domestic leaders and global players alike pursuing multi\u2011agonist approaches, <strong>HRS\u20114729&#8217;s<\/strong> Phase II entry keeps <strong>Hengrui Pharmaceuticals<\/strong> in the leading pack of China&#8217;s incretin\u2011based drug race.<\/li>\n\n\n\n<li><strong>Portfolio Strength:<\/strong> The approval reinforces <strong>Hengrui&#8217;s<\/strong> strategy of building a broad metabolic disease franchise on top of its established oncology pipeline, leveraging its in\u2011house peptide drug discovery capabilities.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial conduct, efficacy outcomes, and commercial potential for HRS\u20114729. Actual results may differ due to risks including Phase II safety and efficacy data, regulatory decisions, and competitive dynamics in the metabolic disease market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260813_YJKD.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260813_YJKD.\"><\/object><a id=\"wp-block-file--media-459487c5-c71f-4847-ac44-1cfd6dd1a876\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260813_YJKD.pdf\">600276_20260813_YJKD<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260813_YJKD.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-459487c5-c71f-4847-ac44-1cfd6dd1a876\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS\u20114729 has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,39,2586,4228,852],"class_list":["post-74989","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-diabetes","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS\u20114729 has received clinical trial approval from the National Medical Products Administration (NMPA) to proceed with Phase II clinical trials in adult patients with type 2 diabetes. The clearance advances one of China&#039;s growing pipeline of next\u2011generation incretin\u2011based metabolic therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=74989\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS\u20114729 has received clinical trial approval from the National Medical Products Administration (NMPA) to proceed with Phase II clinical trials in adult patients with type 2 diabetes. The clearance advances one of China&#039;s growing pipeline of next\u2011generation incretin\u2011based metabolic therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=74989\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T05:37:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T05:37:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74989#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74989\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes\",\"datePublished\":\"2026-08-17T05:37:24+00:00\",\"dateModified\":\"2026-08-17T05:37:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74989\"},\"wordCount\":374,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Diabetes\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74989#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74989\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=74989\",\"name\":\"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-17T05:37:24+00:00\",\"dateModified\":\"2026-08-17T05:37:25+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS\u20114729 has received clinical trial approval from the National Medical Products Administration (NMPA) to proceed with Phase II clinical trials in adult patients with type 2 diabetes. The clearance advances one of China's growing pipeline of next\u2011generation incretin\u2011based metabolic therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74989#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74989\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74989#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS\u20114729 has received clinical trial approval from the National Medical Products Administration (NMPA) to proceed with Phase II clinical trials in adult patients with type 2 diabetes. The clearance advances one of China's growing pipeline of next\u2011generation incretin\u2011based metabolic therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=74989","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS\u20114729 has received clinical trial approval from the National Medical Products Administration (NMPA) to proceed with Phase II clinical trials in adult patients with type 2 diabetes. The clearance advances one of China's growing pipeline of next\u2011generation incretin\u2011based metabolic therapies.","og_url":"https:\/\/flcube.com\/?p=74989","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-17T05:37:24+00:00","article_modified_time":"2026-08-17T05:37:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=74989#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=74989"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes","datePublished":"2026-08-17T05:37:24+00:00","dateModified":"2026-08-17T05:37:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=74989"},"wordCount":374,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Diabetes","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=74989#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=74989","url":"https:\/\/flcube.com\/?p=74989","name":"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-17T05:37:24+00:00","dateModified":"2026-08-17T05:37:25+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS\u20114729 has received clinical trial approval from the National Medical Products Administration (NMPA) to proceed with Phase II clinical trials in adult patients with type 2 diabetes. The clearance advances one of China's growing pipeline of next\u2011generation incretin\u2011based metabolic therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=74989#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=74989"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=74989#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS\u20114729, a Triple\u2011Agonist Peptide Drug for Type 2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=74989"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74989\/revisions"}],"predecessor-version":[{"id":74991,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74989\/revisions\/74991"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=74989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=74989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=74989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}